RP-A501 Shows Clean Safety in First Three Danon Disease Patients, FDA Talks Underway
RCKT sits 24% above its 52-week low of $2.53.
Summary
Rocket's gene therapy RP-A501 cleared a key safety hurdle in the first three patients of its pivotal Phase 2 Danon disease trial under a modified protocol. No thrombotic microangiopathy, capillary leak syndrome, or other significant safety issues emerged—a critical de-risking event given prior safety concerns. The company is now engaging with the FDA to align on dosing additional patients and completing the 12-patient study, with a regulatory update expected in H2 2026. This follows the $180M priority review voucher sale in June, which strengthened the balance sheet. The clean safety data and FDA engagement meaningfully increase the probability of trial completion and eventual approval, a major catalyst for a $340M market cap biotech.
Updates
· Benzinga — Shares rose 7.5% on the news, and the company is in active FDA discussions to align on dosing the remaining nine patients.
At the time of this announcement, RCKT was trading at $3.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $339.6M. The 52-week trading range was $2.53 to $5.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.